Story
Magnesium L-Threonate (Magtein)
Last updated
In one pass Magnesium L-threonate is a magnesium supplement advertised as good for memory and sleep, and as the only magnesium that gets into the brain.
Educational content, not medical advice — consult a clinician.
Story path
Chapter 1
What magnesium threonate is
Magnesium L-threonate is a magnesium supplement advertised as good for memory and sleep, and as the only magnesium that gets into the brain. Once swallowed, it comes apart in the gut into magnesium ions and threonate, and in the blood it is no different from any other magnesium. The claim that it is better for the brain than ordinary magnesium currently rests on one rat study and one small, company-funded human trial. Whether it works, whether it is worth the extra money, and whether it suits you are three separate questions.
Magnesium L-threonate (Mg-L-T) is a salt of magnesium and L-threonic acid. L-threonic acid is one of the small molecules left when vitamin C breaks down. That chemical identity proves neither a special brain benefit nor safety.
Magnesium supplements can cause diarrhea. When kidney function is impaired, the body is less able to clear extra magnesium, and the risk of toxicity rises. Magnesium also affects the absorption of some antibiotics and of oral bisphosphonates (a class of osteoporosis drugs). If you have kidney disease or take medication, ask a doctor or pharmacist whether supplementing suits you and how to space it from your medicines.
Magnesium L-threonate (Mg-L-T) is a salt of magnesium and L-threonic acid. L-threonic acid is one of the small molecules left when vitamin C breaks down. That chemical identity proves neither a special brain benefit nor safety.
Magnesium supplements can cause diarrhea. When kidney function is impaired, the body is less able to clear extra magnesium, and the risk of toxicity rises. Magnesium also affects the absorption of some antibiotics and of oral bisphosphonates (a class of osteoporosis drugs). If you have kidney disease or take medication, ask a doctor or pharmacist whether supplementing suits you and how to space it from your medicines.
Background · From a lab paper to a supplement brand
This compound became a hit in the supplement market mainly through a marketing narrative, not through a series of human trials:In 2010, Guosong Liu, then a neuroscientist at MIT (also affiliated with Tsinghua University), published Slutsky 2010 in the journal Neuron with colleagues from Susumu Tonegawa's lab. After rats were given magnesium L-threonate, magnesium rose in their cerebrospinal fluid (CSF, the fluid that bathes the brain and spinal cord), and they did better on several learning and memory tests.Liu's team founded a company, Magceutics. The molecule was later sold in the U.S. under the brand name Magtein™, distributed by AIDP, a California ingredient company.Magtein™ was then licensed to many supplement brands in the U.S., Europe and China (Life Extension, Pure Encapsulations, Jarrow, Doctor's Best, Now Foods and others all sell a Magtein version).In recent years, riding the sleep, anxiety and memory talk on Huberman, Joe Rogan and TikTok, more and more Magtein products have appeared. A month's supply usually costs several times as much as magnesium citrate or glycinate providing the same amount of elemental magnesium.
Mechanism · The salt comes apart once it is inside
Picture a magnesium salt as a car plus a passenger: threonate is the car, the magnesium ion is the passenger. And the drop-off is in the gut, not in the brain.Magnesium salts dissociate in water. Every salt does that; it is not a special trick of magnesium L-threonate. Once the capsule you swallowed dissolves in stomach and intestinal fluid, the magnesium ion and the threonate go their separate ways:
The magnesium ion is pulled into gut-wall cells by channel proteins, or seeps through the gaps between cells. Those channels recognize the magnesium ion itself, positively charged and wrapped in a shell of water molecules. They do not care which anion it was paired with a moment ago.Threonate is a small acid on the breakdown path of ascorbic acid (vitamin C). The body can metabolize it, but that does not establish its safety at every dose or in every group of people.
Once magnesium is in the blood, physiology describes its forms clearly: most of it is free magnesium ion, some rides on albumin, and a smaller share sits in loose complexes with anions already in the blood. Plasma magnesium is not a swarm of intact magnesium L-threonate molecules drifting in the blood. It is a pool of ions.
So the window in which form can still matter is only one stretch: from mouth to gut wall. After that stretch, whether you swallowed magnesium oxide, citrate or L-threonate, what flows in the blood is the same thing: magnesium ions. For one form to stay special at the brain end, it would first have to show that it is still an intact molecule after this stretch, not a pile of ions. The marketing narrative has never faced that step.
Chapter 2
What the ads claim, and on what
The ads for magnesium L-threonate can be peeled into three layers, and each one has to be checked against the evidence on its own.
Layer 1, the slogans written for ordinary shoppers, for example:
"The only magnesium that gets into the brain""The magnesium for ADHD, anxiety, Alzheimer's disease and insomnia""25% better memory in 12 weeks""A synapse density enhancer"
These lines recur on the Magtein brand site, on countless supplement product pages and in influencer videos.
Layer 2, the evidence the brand uses to back the slogans: nearly all of it points back to two papers. One is a rat study, Slutsky 2010 (Neuron); the other is a human , Liu 2016 (Journal of Alzheimer's Disease, trial code MMFS-01). Guosong Liu is the corresponding author of both, and the founder of the company Magceutics. The brand also lists many related studies in cells and in aged rats, but none of them directly supports a claim about humans.
Layer 3 is the physiology itself, and it answers a different question: can other forms of magnesium reach the brain at all?
Layer 1, the slogans written for ordinary shoppers, for example:
"The only magnesium that gets into the brain""The magnesium for ADHD, anxiety, Alzheimer's disease and insomnia""25% better memory in 12 weeks""A synapse density enhancer"
These lines recur on the Magtein brand site, on countless supplement product pages and in influencer videos.
Layer 2, the evidence the brand uses to back the slogans: nearly all of it points back to two papers. One is a rat study, Slutsky 2010 (Neuron); the other is a human , Liu 2016 (Journal of Alzheimer's Disease, trial code MMFS-01). Guosong Liu is the corresponding author of both, and the founder of the company Magceutics. The brand also lists many related studies in cells and in aged rats, but none of them directly supports a claim about humans.
Layer 3 is the physiology itself, and it answers a different question: can other forms of magnesium reach the brain at all?
Mechanism · Can other forms of magnesium reach the brain
Layer 3 is physiology. In an ordinary adult, plasma magnesium is about 0.75–0.95 mmol/L and cerebrospinal-fluid magnesium about 1.0–1.2 mmol/L. There is already magnesium in the cerebrospinal fluid, and it has only one source: magnesium ions from the blood, whichever salt was swallowed in the first place.So the contrast hidden in the slogan "the magnesium that gets into the brain" (namely, that other magnesium cannot) is false. Magnesium moves from the blood into the brain and the cerebrospinal fluid through transport proteins in cell membranes that recognize the magnesium ion, such as TRPM7 and MagT1. (De Baaij 2015, a review in Physiological Reviews, covers how magnesium is absorbed, transported and excreted.) By this physiology, any form of oral magnesium that fills a deficit in the body takes the same route. "It gets into the brain" is not a meaningful physiological distinction.
One honest addition: which magnesium salt raises magnesium in the human brain a little more has never been compared directly in people. The only comparison comes from rats (Slutsky 2010). The marketing turned that animal result into a human fact. Between Layer 1 (the words a lay reader hears) and Layer 3 (the physiology) sits a thin shell held up by two papers.
Mechanism · What magnesium does in the brain
Marketing says it gets into the brain. Physiology says every form of magnesium does. But neither side spells out one thing: what magnesium is doing once it is in. Without knowing that job, "can it get in" is only a slogan.The brain's main excitatory signal is glutamate. It docks on receptors at the surface of a neuron, opens a channel, lets positively charged ions rush into the cell, and the neuron fires. One class of these channels is the NMDA receptor. Read it as the kind that only opens when two conditions are true at once.
At rest it is plugged by a magnesium ion. The plug is voltage-sensitive: the inside of the cell is negatively charged, which pulls the positive magnesium into the pore, so the plug sits tight. Only after this neuron has already been activated by other signals, and part of that inner negative charge has been canceled, does the pull loosen. The magnesium is pushed out, and only then does the channel really open.
So: the NMDA receptor lets current through only when glutamate has arrived and this neuron is already excited. It is a coincidence detector (it responds only when two things happen together), and the magnesium plug is the threshold itself.When magnesium runs short: by the mechanism, fewer pores are plugged at any moment, the threshold drops, and the same amount of glutamate fires the neuron more easily. Whether this step is directly linked to the everyday feeling of being tense, sleeping badly or having thoughts that will not stop has not been shown in people. Do not treat it as settled.Filling the deficit puts the plugs back. And the plug does not care which salt it came from: what sits in the pore is a positively charged magnesium ion. The threonate already parted from it in the gut.
With this link in place, the core claim of this story no longer needs authorities to prop it up: any form of magnesium that restores the body's magnesium puts the plugs back. For one form to beat another, it would have to do something different at the plug, not shout louder about whether it can get in.
Numbers · CSF magnesium is already higher than blood
One fact is easy to slide past: cerebrospinal-fluid magnesium is higher than plasma magnesium. The direction itself is worth a pause. If this were only passive leakage, the two sides should drift toward the same level.Cerebrospinal fluid is not blood that leaked into the skull. It is made by a tissue layer called the choroid plexus. Choroid-plexus cells line the walls of the brain's ventricles; on one side they pick things out of the blood and move them in, and on the other they keep out what should not enter. So the makeup of cerebrospinal fluid is actively set, not passively following the blood. Magnesium is set higher than in plasma, which physiology reads as the body protecting the brain's share first.
That has two consequences, both aimed squarely at the marketing narrative:
In ordinary conditions, the brain is not a magnesium-deficient organ. Most of the body's magnesium is stored in bone and muscle, and the cerebrospinal-fluid pool is held very steady. So a high-priced fix for not enough magnesium in the brain first has to answer when the brain is actually short. The reasonable guess is: when the whole body already has a deficit. That is exactly the situation any form of magnesium can fix.CSF magnesium is the water level in the bathtub, not the flow from the tap. It measures the pool of fluid bathing the neurons, not what one synapse did at a given moment, and not whether the plug has returned to the channel mouth. An animal experiment that sees this water level rise is still several steps away from this animal remembers better, and even farther from you will be smarter.
Chapter 3
The animal study behind the claims
The mechanistic foundation of the whole Magtein story is a rat study published in Neuron in 2010 (Slutsky 2010). It is a typical early animal study, and it cannot hold up the human claims the brand has stacked on it.
What the paper did:
It gave rats magnesium L-threonate and compared it with several common magnesium salts, measuring how much magnesium rose in plasma and in cerebrospinal fluid. In the L-threonate group, cerebrospinal-fluid magnesium rose more.In the hippocampus (the part of the brain most closely tied to memory), synapses were denser, and there were more NMDA receptors containing the NR2B subunit.On several learning and memory tests, these rats learned faster and remembered better, and aged rats improved too.
That is an animal result. It is not evidence about human memory.
What the paper did:
It gave rats magnesium L-threonate and compared it with several common magnesium salts, measuring how much magnesium rose in plasma and in cerebrospinal fluid. In the L-threonate group, cerebrospinal-fluid magnesium rose more.In the hippocampus (the part of the brain most closely tied to memory), synapses were denser, and there were more NMDA receptors containing the NR2B subunit.On several learning and memory tests, these rats learned faster and remembered better, and aged rats improved too.
That is an animal result. It is not evidence about human memory.
Evidence · Six limits of the animal study
By the standards any biomedical-methods textbook would list, this paper has six limits:Species: rats are not people. Magnesium metabolism, gut absorption and the transport proteins at the blood-brain barrier all differ.Sample: the typical small numbers of an animal study. The experiments were exploratory, not designed to support conclusions about humans.How to read the comparison: in rats, magnesium L-threonate raised cerebrospinal-fluid magnesium more, and the marketing rewrote this as "other magnesium is poorly absorbed". That overreaches. It describes one difference seen in rats, not a ranking of absorption in people.Replication: in the more than ten years since publication, and within what this story has checked, the key step (that L-threonate raises cerebrospinal-fluid magnesium more than other salts) has not been reproduced by a lab unconnected to this team and brand.Endpoints: more NR2B in the hippocampus and better scores on maze-type tasks are common and fairly easy-to-reach endpoints in animal research. They are not human memory improvement, and still less human Alzheimer's prevention.Interests: the corresponding author, Guosong Liu, later founded a company that promotes this compound. The paper itself is an ordinary academic publication, but readers should know it later became the founding paper of a commercial product line.
Evidence · What it supports and what it does not
What it can support: in rats, magnesium L-threonate is an interesting tool compound. Under the conditions of this study, it raised cerebrospinal-fluid magnesium more than several common magnesium salts did.What it cannot support: "the only magnesium that gets into the human brain", "improves memory in people", "prevents Alzheimer's disease". Those claims cross species, clinical endpoints and diseases, and an animal paper from more than ten years ago cannot carry that weight. Liu's team later ran a human trial of its own, and how much that trial can carry has to be taken apart separately.
Mechanism · A new door, or more traffic
The animal paper reports one core fact: rats given magnesium L-threonate had a larger rise in cerebrospinal-fluid magnesium than rats given several common magnesium salts. That fact has two completely different readings, and the marketing tells only one of them.Reading 1: a new door (the marketing version). Threonate escorts magnesium across the blood-brain barrier, along a route other magnesium cannot take. For this reading to hold, at least two things must be true at once:
the complex never comes apart in the gut or the blood, and reaches the brain's blood vessels as an intact molecule;the blood-brain barrier has a transporter that recognizes this complex, not only the channels that recognize the magnesium ion itself.
Published magnesium physiology describes the second kind: magnesium crosses membranes through pores that recognize the ion, and a pore's size and charge layout are built around a water-wrapped magnesium ion, not around magnesium paired with an organic acid. For the first reading to stand, someone would first have to find that complex-recognizing transporter.
Reading 2: the same door, a little more traffic. Magnesium L-threonate is absorbed a bit more in the gut, or stays in the blood a bit longer, so the plasma-magnesium curve sits higher and flatter. Once plasma magnesium is higher, more of it rides the same transporters into the brain. This reading needs no new mechanism, only a small difference in absorption kinetics, and it is already known that magnesium salts differ in absorption.
How do you tell the two readings apart? The test is concrete. If it is the same door, then raising the control group's plasma-magnesium curve to match the L-threonate group should erase the cerebrospinal-fluid gap; if it really is a new door, the gap stays. That is exactly the experiment an independent lab would run, and it does not appear in the literature this story has checked.
Until that step is done, "the only magnesium that gets into the brain" is missing more than sample size. It is missing a mechanism shown to exist.
Evidence · Why animal doses do not transfer
Before reading any animal supplement paper, check two things: how the substance was given and how much.Injection skips the entire gut. And the gut is the one stretch where form has any chance to matter: which salt the magnesium came from, how much is absorbed and how fast are all decided there. An experiment that skips the gut, however pretty its result, cannot tell you what happens when you swallow it.
An animal's dose per kilogram also cannot be multiplied by your own body weight. Smaller animals have a faster metabolism per unit of body weight. Given the same dose per kilogram, a small animal clears it faster, and the shape of its blood-concentration curve is different. So the accepted way to convert an animal dose to a human one is by body surface area, not by body weight, and after conversion the human dose per kilogram is always clearly smaller than the animal's. Seeing an animal study's dose per kilogram and multiplying it by your own weight is one of the most common overreaches in supplement marketing.
One more layer is the easiest to skip: were these animals deficient to begin with? Giving more to an animal that is not short measures what happens when you add more. Your real question is often I already have a deficit; what happens when I fill it. Those are two different questions, and the answers can be completely different. When this story keeps saying filling the deficit, it means the second one.
Chapter 4
The human trial the brand cites most
Liu 2016 (trial code MMFS-01) is the human evidence the brand cites most. It was a randomized, double-blind, placebo-controlled trial, funded by Neurocentria, the company where Guosong Liu worked.
Design:
Participants: adults aged 50–70 who felt their memory had slipped and who also had sleep problems and mild-to-moderate anxiety, but no dementia diagnosis, enrolled at one research center in Miami.Numbers: 51 people were randomized and 44 were analyzed (23 on magnesium L-threonate, 21 on placebo).Dose and duration: MMFS-01 (that is, magnesium L-threonate) at 1.5–2 g a day by body weight, for 12 weeks.Primary endpoint: tests from 4 cognitive domains (attention, working memory, executive function and episodic memory) combined into one composite score.
Reported result: the composite score rose more than in the placebo group. Comparing the speed on the executive-function test against normative data gave a brain age about 9 years younger. The brand quotes these two results again and again. The same paper also states that the placebo effects on sleep and anxiety were so strong that whether magnesium L-threonate did anything for either could not be determined.
Design:
Participants: adults aged 50–70 who felt their memory had slipped and who also had sleep problems and mild-to-moderate anxiety, but no dementia diagnosis, enrolled at one research center in Miami.Numbers: 51 people were randomized and 44 were analyzed (23 on magnesium L-threonate, 21 on placebo).Dose and duration: MMFS-01 (that is, magnesium L-threonate) at 1.5–2 g a day by body weight, for 12 weeks.Primary endpoint: tests from 4 cognitive domains (attention, working memory, executive function and episodic memory) combined into one composite score.
Reported result: the composite score rose more than in the placebo group. Comparing the speed on the executive-function test against normative data gave a brain age about 9 years younger. The brand quotes these two results again and again. The same paper also states that the placebo effects on sleep and anxiety were so strong that whether magnesium L-threonate did anything for either could not be determined.
Evidence · Six weak points in this trial
The limits of this trial:Sample: 44 people is exploratory pilot territory for a cognitive intervention, not a confirmatory trial. For comparison, the FINGER trial of cognition in older adults randomized 1260 people and ran for 2 years, and PREDIMED, a large nutrition trial (its endpoint was cardiovascular events), had about 7447. On size alone, the gap is 30–150-fold.Duration: 12 weeks. Cognitive decline itself unfolds over years, even decades.Funding and analysis: the trial was funded by Neurocentria and designed jointly by the company and the research center. The company ran the statistical analysis of the cognitive tests and of the body-magnesium measures itself, and the company wrote the paper (the paper's funding statement says so). The first author, Guosong Liu, worked at that company. In a drug trial, overlap on this scale is usually balanced by independent oversight and third-party analysis; the supplement market has no such constraint.Endpoint design: the primary endpoint is a composite of four tests, and a composite leaves the analyst a lot of room. Taken one by one, only the executive-function test (Trail Making Test part B, TMT-B) showed a statistically significant overall effect across the treatment period; working memory differed only at week 6, and attention and episodic memory showed no difference. According to ClinicalTrials.gov (NCT02363634), the trial was registered only after it was finished, so outsiders cannot check whether the endpoints were fixed in advance."A brain 9 years younger": this figure comes from the TMT-B test alone, estimated by comparing it with normative data from another study. It is not something that was measured directly. Slogans such as "25% better memory" have no matching result in the paper.Replication: a few small human trials have followed, but with different populations, endpoints or formulations, and with authors or suppliers still connected to the brand. Within what this story has checked, no team unconnected to the brand has reproduced these results with the same cognitive endpoints. In biomedicine, a single small trial usually means worth a larger study, not ready to use in product marketing.
Evidence · Set against the wider evidence
Set against the wider evidence, the size gap becomes plain:Boyle 2017 (Nutrients), a systematic review, included 18 studies, all in people already prone to anxiety (mild anxiety, premenstrual syndrome, the postpartum period, high blood pressure). Some found that self-rated anxiety fell after magnesium supplementation; postpartum anxiety did not improve. The authors concluded that the evidence is suggestive but of poor quality, and that well-designed are needed to confirm it. It cannot be stretched to "magnesium eases anxiety in anyone", and none of the included studies found magnesium L-threonate better than magnesium citrate or glycinate.De Baaij 2015 (Physiological Reviews), the standard review of magnesium physiology, describes absorption, transport and excretion entirely in terms of the magnesium ion, not in terms of which salt it came from.The 2022 magnesium fact sheet for health professionals from the U.S. National Institutes of Health Office of Dietary Supplements (NIH ODS) likewise does not single out magnesium L-threonate as better for the brain.
Seen this way: Liu 2016 is not the peak of the Magtein evidence; it is nearly the whole of it. Forty-four people, company funding with the company running the cognitive analysis, a paper written by the first author's employer, a composite endpoint, registration after the fact, no independent replication: each item alone is survivable, but stacked together, this one paper cannot bear the scientific weight of an entire supplement category.
Chapter 5
Most people need ordinary magnesium
Reduce the whole thing to a wallet question: how should the money for magnesium be spent?
First, the big picture: according to the U.S. National Health and Nutrition Examination Survey (NHANES), about 50% of Americans get less magnesium from their diet than the Estimated Average Requirement (, the amount that meets the needs of half of healthy people). But low intake is not the same as magnesium deficiency: in healthy people the kidneys compensate by excreting less, and symptomatic deficiency caused by low intake alone is uncommon. So for people whose intake is low, bringing magnesium back up is worthwhile; which magnesium is a separate question.
The U.S. Recommended Dietary Allowance (, NIH ODS): men 400 mg at 19–30 and 420 mg from 31; women 310 mg at 19–30 and 320 mg from 31; in pregnancy, add 40 mg to the amount for that age.
The first choice is food: 1/2 cup of cooked spinach has about 78 mg, 1 ounce of pumpkin seeds about 156 mg, 1 ounce of almonds about 80 mg, 1 cup of cooked black beans about 120 mg, 1 cup of cooked brown rice about 85 mg, and 1 ounce of dark chocolate with 70% or more cocoa about 64 mg. Someone who regularly eats leafy greens, nuts and whole grains can reach the RDA from food alone. For them this question is closed, and no supplement is needed.
First, the big picture: according to the U.S. National Health and Nutrition Examination Survey (NHANES), about 50% of Americans get less magnesium from their diet than the Estimated Average Requirement (, the amount that meets the needs of half of healthy people). But low intake is not the same as magnesium deficiency: in healthy people the kidneys compensate by excreting less, and symptomatic deficiency caused by low intake alone is uncommon. So for people whose intake is low, bringing magnesium back up is worthwhile; which magnesium is a separate question.
The U.S. Recommended Dietary Allowance (, NIH ODS): men 400 mg at 19–30 and 420 mg from 31; women 310 mg at 19–30 and 320 mg from 31; in pregnancy, add 40 mg to the amount for that age.
The first choice is food: 1/2 cup of cooked spinach has about 78 mg, 1 ounce of pumpkin seeds about 156 mg, 1 ounce of almonds about 80 mg, 1 cup of cooked black beans about 120 mg, 1 cup of cooked brown rice about 85 mg, and 1 ounce of dark chocolate with 70% or more cocoa about 64 mg. Someone who regularly eats leafy greens, nuts and whole grains can reach the RDA from food alone. For them this question is closed, and no supplement is needed.
In practice · Choosing cheap or premium magnesium
The second choice: an ordinary magnesium supplement (when food falls short). The options are not complicated:Magnesium citrate: one of the forms that dissolve well and are absorbed fairly completely (NIH ODS: magnesium in the aspartate, citrate, lactate and chloride forms is absorbed more completely than magnesium oxide and sulfate). It is cheap, and for most people it is the most practical first pick. A common amount is 200 mg of elemental magnesium a day.Magnesium glycinate (glycinate or bisglycinate): some people find it gentler on the stomach and like to take it in the evening. No reliable human comparison shows it beats other magnesium salts for sleep or anxiety.Magnesium chloride and lactate: also well absorbed.Avoid magnesium oxide on its own: it is poorly absorbed (as one ingredient in a combined formula it is fine).Whatever the form: for adults (from age 9), the tolerable upper intake level () for magnesium from supplements and medicines is 350 mg a day; magnesium from food does not count toward it. Doses above it are treatment doses and should be used under a doctor's guidance.
The third choice: magnesium L-threonate (Magtein), which costs several times as much per month as the options above. It supplies magnesium, but its safety still depends on dose, kidney function and other medicines, not simply on the name of the salt. To be clear: no human study shows it does better than magnesium citrate at the actual job of filling a magnesium deficit. Slutsky 2010 is a rat study, and Liu 2016 is a single company-funded trial with 44 people.
Are you willing to pay several times more each month for a cognitive boost that may exist and has not been independently reproduced? This is a real wallet question with no standard answer. But be clear that what you are paying is a premium for one animal study and one small trial, not the price of a smarter magnesium.
Evidence · Where money for cognition does more
If you genuinely want to invest more in cognitive health, the same budget and time spent in these directions rests on firmer evidence than magnesium L-threonate:A combined lifestyle program: the FINGER trial took 1260 older adults at raised risk of cognitive decline and combined diet, exercise, cognitive training and management of vascular risk for 2 years. Overall cognitive test scores ended up better than in the control group.Exercise: about 150 minutes a week of moderate aerobic activity plus 2 strength sessions is the standard exercise advice. In a combined trial such as FINGER, its own share of the effect on cognition cannot be separated out.Hearing: get a hearing check, and use a hearing aid when you need one. The 2024 report of the Lancet Commission on dementia lists untreated hearing loss among the largest modifiable risk factors.Blood pressure, blood glucose, cholesterol, smoking and social isolation: all appear among the modifiable factors in the same report, which estimates that all 14 together account for about 45% of dementia risk.Eating patterns such as Mediterranean, DASH or MIND, and 7–9 hours of sleep a night: their links with cognition come mainly from observational studies (they show an association, not that the habit caused the difference).
This is not a scam alert: magnesium L-threonate does supply magnesium, and whether to take it and whether it suits you still depend on diet, kidney function and medication. The problem is the distance between the marketing and the evidence: "the only magnesium that gets into the brain" is wrong, and "5 times smarter than other magnesium" has no evidence.
> Magnesium L-threonate is magnesium, not magic. If your intake is low, fill it with food first, then add a cheap magnesium (citrate or glycinate) if needed. Paying several times more for Magtein buys a premium on a marketing claim, not a better brain.
>
> If you really want to protect cognition, keep that price difference and spend it on exercise, good food, a hearing check and a better sleep environment. The evidence behind each of these is stronger than the evidence behind magnesium L-threonate.
Mechanism · Why a stronger magnesium hits a ceiling
Even granting it everything: suppose magnesium L-threonate really can push brain magnesium higher than other forms. Give it that step for free, and higher still does not automatically mean better, because the site where it acts fills up.Magnesium's job at the neuron is to plug the channel mouth and hold the excitation threshold up. The number of channel mouths is limited. Once every one that should be plugged is plugged, extra magnesium has no new pore to fill. For a site-limited mechanism like this, the dose-response relationship is naturally a curve that is steep first, then flat: in the deficit stretch, every bit you add pays off; once the gap is closed, the curve lies down.
The body also brakes at both ends:
At the gut: the active absorption channels for magnesium fill up. The larger the dose, the smaller the share that comes in through the channels, and the rest can only seep slowly through the gaps between cells. So the more you take, the lower the fraction absorbed. Magnesium left unabsorbed in the gut draws water in and can cause diarrhea, and diarrhea is not the only risk of taking too much.At the kidney: when kidney function is normal, excess magnesium can leave in the urine. With impaired kidney function, or when intake is excessive, this control cannot guarantee normal blood magnesium, and hypermagnesemia (too much magnesium in the blood) can still occur.
Put these three facts together and the selling point a magnesium that pushes magnesium higher has a hole in it: the threshold mechanism saturates, and the gut and kidneys regulate too, though that regulation does not make excess intake safe. What decides whether you benefit is how large your original deficit was, not how fancy the carrier is. That is also why reviews of magnesium physiology describe absorption, transport and excretion in terms of the magnesium ion alone, not the salt it came from.
References · 8
- National Institutes of Health, Office of Dietary Supplements. (2022). Magnesium — Fact Sheet for Health Professionals. ods.od.nih.gov/factsheets/Magnesium-HealthProfessional
- de Baaij, J. H. F., Hoenderop, J. G. J., & Bindels, R. J. M. (2015). Magnesium in man: implications for health and disease. Physiological Reviews, 95(1), 1–46. 10.1152/physrev.00012.2014
- Slutsky, I., Abumaria, N., Wu, L.-J., Huang, C., Zhang, L., Li, B., Zhao, X., Govindarajan, A., Zhao, M.-G., Zhuo, M., Tonegawa, S., & Liu, G. (2010). Enhancement of learning and memory by elevating brain magnesium. Neuron, 65(2), 165–177. 10.1016/j.neuron.2009.12.026
- Liu, G., Weinger, J. G., Lu, Z.-L., Xue, F., & Sadeghpour, S. (2016). Efficacy and safety of MMFS-01, a synapse density enhancer, for treating cognitive impairment in older adults: a randomized, double-blind, placebo-controlled trial. Journal of Alzheimer's Disease, 49(4), 971–990. 10.3233/JAD-150538
- Boyle, N. B., Lawton, C., & Dye, L. (2017). The effects of magnesium supplementation on subjective anxiety and stress — a systematic review. Nutrients, 9(5), 429. Despite the id, this is a systematic review of magnesium for subjective anxiety and stress, not a depression trial: 18 studies, all in samples vulnerable to anxiety (mildly anxious, premenstrual syndrome, postpartum, hypertension); positive effects in 4 of 8 anxious-sample studies, 4 of 7 PMS studies and 1 of 2 hypertension studies; no effect postpartum; no study used a validated stress measure; evidence quality poor (abstract, PMID 28445426). 10.3390/nu9050429
- Ngandu, T., Lehtisalo, J., Solomon, A., et al. (2015). A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. The Lancet, 385(9984), 2255-2263. Multidomain intervention significantly improved overall cognitive performance vs control. 10.1016/S0140-6736(15)60461-5
- Estruch, R., Ros, E., Salas-Salvadó, J., Covas, M.-I., Corella, D., Arós, F., et al. (2018). Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. New England Journal of Medicine, 378(25), e34. PREDIMED RCT (~7,447 high-risk adults); a Mediterranean diet supplemented with mixed nuts (or EVOO) reduced major cardiovascular events versus a control low-fat diet. (First published 2013; retracted in 2018 over randomization issues and republished the same year with corrected data.). 7,447 adults aged 55-80 (57% women) at high cardiovascular risk; median 4.8 years. Events 3.8% (olive oil), 3.4% (nuts), 4.4% (control); adjusted HR 0.69 (0.53-0.91) and 0.72 (0.54-0.95). Results similar after omitting 1,588 participants whose assignments departed from protocol (household members enrolled without randomisation, some participants at 1 of 11 sites assigned without randomisation, inconsistent use of randomisation tables at another site) (abstract, PMID 29897866). 10.1056/NEJMoa1800389
- Livingston, G., Huntley, J., Liu, K. Y., et al. (2024). Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. The Lancet, 404(10452), 572-628. Adds high LDL cholesterol and untreated vision loss for 14 modifiable factors totaling ~45% of dementia risk. 10.1016/S0140-6736(24)01296-0